Results showed that Tenuifoliside-C miR-630 expression was increased in gastric cancer compared with that in adjacent and normal control tissues for high expression of miR-630 was more likely to be detected in gastric cancer specimens, which indicating its possible participation on carcinogenesis. It is also found that miR-630 expression was closely related to gastric cancer invasion, lymph node metastasis, distant metastasis and TNM stage 
for high expression of miR-630 was more frequently to be detected in tumors with deep invasion, lymph node metastasis, distant metastasis or advanced TNM stage, suggesting the possible participation of miR-630 on gastric cancer invasion and metastasis. Together with the above evidence, it was thus proposed that miR-630 may play important roles in gastric cancer carcinogenesis and progression. As miR-630 expression was found to be associated with gastric cancer invasion and metastasis, considering the invasion of cancer to nearby tissues and metastasis to distal tissues are crucial factors affecting the prognosis of patients, miR-630 might be a potential prognostic marker for Isochlorogenic-acid-C patients with gastric cancer. In order to investigate the prognostic role of miR-630 on gastric cancer, we performed Kaplan-Meier analysis of overall survival. Results showed that patients with gastric cancer of high miR-630 expression tend to have worse overall survival in comparison to patients with tumor of low miR-630 expression, which suggested that miR-630 expression was a prognostic marker for patients with gastric cancer. To further evaluate the prognostic value of miR630 in gastric cancer, we performed Cox proportional hazards model which was adjusted for gender, age and TNM stage of patients. Results proved that increased miR-630 expression was a marker of poor overall survival independent of adjusted factors, thus, miR-630 could be utilized to determine patients’ prognosis with out considering TNM stage. These results indicated that miR-630 could constitute a molecular prognostic marker additive to TNM stage for patients with gastric cancer, identifying high risk individuals who are more likely to have tumor relapse in clinical practice, thus, good candidates to receive more aggressive treatment. These results were in consistent with investigations focused on non-small cell lung cancer, indicating the consistence of miR-630 function in these types of tumor. Thus, the positive linkage between miR-630 overexpression and poor prognosis may not only be used for identifying gastric cancer patients with higher risk of early tumor relapse but also for providing valuable clues to understand the possible mechanism of gastric cancer invasion and metastasis. In conclusion, we have proved that miR-630 expression was increased in gastric cancer and associated with tumor progression. The present study also demonstrated for the first time that miR630 expression was an independent prognostic factor of patients with gastric cancer. Therefore, it is possible that miR-630 may play an important role in invasiveness and metastasis of gastric cancer. It is also possible that miR-630 serves as prognostic marker in clinical practice and even the inhibition for miR-630 using specific inhibitors may become a new therapeutic.